

# $\beta_2$ -Adrenoreceptor Agonist Inhalation During Ex Vivo Lung Perfusion Attenuates Lung Injury

Takeshi Kondo, MD, Fengshi Chen, MD, PhD, Akihiro Ohsumi, MD, Kyoko Hijiya, MD, Hideki Motoyama, MD, Terumasa Sowa, MD, Keiji Ohata, MD, Mamoru Takahashi, MD, Tetsu Yamada, MD, Masaaki Sato, MD, PhD, Akihiro Aoyama, MD, PhD, and Hiroshi Date, MD, PhD

Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

**Background.** Attenuation of ischemia reperfusion injury (IRI) is important in lung transplantation. Our group previously reported that  $\beta_2$ -adrenoreceptor agonist inhalation during the period before procurement successfully attenuated IRI in donated lungs after cardiac death. We therefore hypothesized that  $\beta_2$ -adrenoreceptor agonist inhalation during ex vivo lung perfusion (EVLP) after procurement might also have a protective effect.

**Methods.** Cardiac-dead beagles were left at room temperature for 210 minutes, and all lungs were subsequently procured and subjected to EVLP for 240 minutes. The beagles were allocated to 2 groups: the  $\beta_2$  group (receiving an aerosolized  $\beta_2$ -adrenoreceptor agonist 20 minutes after initiation of EVLP;  $n = 7$ ) and the control group (receiving an aerosolized control solvent at the same time point;  $n = 6$ ). Physiologic data, including lung function, were evaluated during EVLP.

**Results.** The  $\beta_2$  group showed significantly lower peak airway pressure and pulmonary artery pressure than the control group. Dynamic pulmonary compliance was higher, pulmonary vascular resistance (PVR) was lower, and the wet-to-dry lung weight ratio was lower in the  $\beta_2$  group than in the control group. Cyclic adenosine monophosphate (cAMP) and total adenosine nucleotide (TAN) levels in lung tissue after EVLP were higher in the  $\beta_2$  group than in the control group. The  $\beta_2$  group also showed more cystic fibrosis transmembrane conductance regulator (CFTR) gene expression.

**Conclusions.** After procurement,  $\beta_2$ -adrenoreceptor agonist inhalation during EVLP attenuates lung injury in a canine model of organ donation after cardiac death.

(Ann Thorac Surg 2015;100:480–6)

© 2015 by The Society of Thoracic Surgeons

The chronic shortage of brain-dead donors is a problem in clinical lung transplantation. A practical method to resolve this problem is to transplant lungs acquired by donation after cardiac death (DCD). Warm ischemia inevitably occurs in DCD donors and may cause ischemia reperfusion injury (IRI) after lung transplantation. Severe IRI leads to primary graft dysfunction and remains a significant cause of early morbidity and mortality after lung transplantation [1]. Therefore, it is important to attenuate IRI caused by warm ischemia in DCD donors. Many groups have studied IRI caused by warm ischemia. Our group previously reported that  $\beta_2$ -adrenoreceptor agonist inhalation before procurement during donation successfully attenuated IRI in a DCD model [2, 3]. Steen and colleagues [4] introduced ex vivo lung perfusion (EVLP) to evaluate the function of DCD donor lungs before transplantation, and this system was subsequently developed for clinical use by a Toronto group [5]. EVLP has since been used not only for the assessment but also for the reconditioning of marginal and DCD donor lungs [5–7]. To date, several studies have been conducted using EVLP as a drug delivery system [8–12].

Accepted for publication Feb 10, 2015.

Address correspondence to Dr Date, Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan; e-mail: [hdate@kuhp.kyoto-u.ac.jp](mailto:hdate@kuhp.kyoto-u.ac.jp).

We previously demonstrated that  $\beta_2$ -adrenoreceptor agonist inhalation during the period before procurement attenuated IRI, but it is unknown if  $\beta_2$ -adrenoreceptor agonist inhalation after procurement could affect the injured lungs. We hypothesized that  $\beta_2$ -adrenoreceptor agonist inhalation during EVLP after procurement would also have a protective effect.

## Material and Methods

### Animals

All animals used in this study received humane care in compliance with the Principles of Laboratory Animal Care, formulated by the National Society for Medical Research, and the Guide for the Care and Use of Laboratory Animals, prepared by the National Institutes of Health (NIH publication No. 86-23, revised 1996). The study protocol was approved by the Ethics Committee of the Graduate School of Medicine at Kyoto University, Japan (Medkyo 13257).

### Study Design

The study time line is shown in Figure 1. The donor dogs were anesthetized through an intramuscular injection of midazolam (0.5 mg/kg), xylazine (0.25 mg/kg), and atropine sulfate (0.05 mg/kg). They were intubated and




Fig 1. Time line of the study. (EVLP, *ex vivo* lung perfusion; KCl, potassium chloride.)

mechanically ventilated with a tidal volume of 25 mL/kg, a respiration rate of 15 breaths/min, a positive end-expiratory pressure (PEEP) of 5.0 cm H<sub>2</sub>O, and a fraction of inspired oxygen (FiO<sub>2</sub>) of 1.0. The dogs were euthanized by intravenous administration of potassium chloride (0.5 mEq/kg), without heparinization. The ventilators were then removed and the tracheal tubes exposed to room atmosphere.

The donor dogs were left at room temperature (23°C) for 210 minutes. A median sternotomy was performed, and a pulmonary artery flush was performed on all donors 210 minutes after cardiac arrest using ET-Kyoto solution (Otsuka Pharmaceutical Co Ltd, Tokyo, Japan), an extracellular preservation solution we developed for clinical lung transplantation [13]. Before use, the ET-Kyoto solution was stored at 4°C without heparin. The flush was performed with ventilation, 30 cm above the donor's chest. Just after flushing, the donor lungs were retrieved and subjected to EVLP.

Before EVLP, we collected blood from the other dogs. We administered 5,000 IU heparin and collected blood from the incised left atrial appendage, superior vena cava, and inferior vena cava. The collected blood was centrifuged with a cell-saving device (Cell Saver 5; Haemonetics Corp, Braintree, MA) through a leukocyte filter, stored with citrate phosphate dextrose adenine (Sepacell Integra CA; Asahi Kasei Medical Co Ltd, Tokyo, Japan), and used to prime the EVLP circuit.

The lungs were placed in an XVIVO chamber (Vitrolife, Denver, CO). The pulmonary artery was directly cannulated and connected to the perfusion circuit. The left atrium was open so that the left atrial pressure was always 0 mm Hg. The EVLP perfusate consisted of STEEN solution (XVIVO perfusion, Englewood, CO) (1,500 mL) with approximately 650 mL of concentrated red blood cells, methylprednisolone (500 mg), heparin (10,000 IU), cefazolin (500 mg), and THAM SET (Otsuka Pharmaceutical Factory, Inc, Tokushima, Japan). A centrifugal pump at a constant flow rate drove the perfusate, and the flow was started at 10% of the full flow rate at room temperature. The temperature of the perfusate was gradually increased to 37°C. Twenty minutes after initiation of EVLP (when the temperature of the perfusate reached 32°C), ventilation was initiated with an FiO<sub>2</sub> of 0.25, a tidal volume of 15 mL/kg, a frequency of 12 breaths/min, and a PEEP of 5 cm H<sub>2</sub>O. Deoxygenation of the lung perfusate was initiated with a gas mixture of nitrogen (86%), carbon

dioxide (8%), and oxygen (6%). The perfusate flow rate was gradually increased to the full flow rate, which was 40% of the estimated cardiac output (100 mL/kg), 60 minutes after initiation of EVLP. The canine lungs were subjected to EVLP for a total of 240 minutes.

### Study Groups

The donor lungs were divided into 2 groups: (1) the  $\beta_2$  group ( $n = 7$ ), which inhaled the  $\beta_2$ -adrenoreceptor agonist (0.01% procaterol [3.5 mL] inhalation solution [350  $\mu$ g procaterol]) for 30 minutes, starting at the same time as ventilation (20 minutes after initiation of EVLP) and (2) the control group ( $n = 6$ ), which inhaled the control solvent (3.5 mL) in the same setting.

### Functional Assessment

Physiologic data were obtained 20, 70, 120, 180, and 240 minutes after initiation of EVLP. Dynamic pulmonary compliance was defined as the tidal volume/(peak airway pressure–PEEP) mL/cm H<sub>2</sub>O. Pulmonary vascular resistance (PVR) was calculated as (pulmonary artery pressure  $\times$  80)/pulmonary artery flow (dynes/s/cm<sup>5</sup>). Blood gas analysis of the perfusate from the lung was performed after 10 minutes of exposure to an FiO<sub>2</sub> of 1.0.

### Lung Wet Weight-to-Dry Weight Ratio

The entire right lung was used to calculate the wet weight-to-dry weight ratio (WDR) 240 minutes after initiation of EVLP. Wet weight (in milligrams) was measured first, and the dry weight (in milligrams) was measured after the lung had been dried overnight at 180°C. We measured dry weight multiple times at intervals and found that the weights were the same at all time points. The WDR was calculated by dividing the wet weight by the dry weight.

### Adenine Nucleotide Levels

Peripheral lung tissue samples were collected from the left lungs 240 minutes after initiation of EVLP. The concentrations of adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) were measured using high-performance liquid chromatography (Shim-pack CLC-ODS column; 15 cm  $\times$  6.0 mm; Shimadzu Corp, Kyoto, Japan). Total adenosine nucleotide (TAN) values were calculated as previously reported [3]. We were unable to collect data from two cases in the  $\beta_2$  group and one case in the control group

due to trouble with the lyophilization machine. Therefore, in total we evaluated 5 cases in the  $\beta_2$  group and 5 cases in the control group.

### Cyclic Adenosine Monophosphate Levels

We evaluated cyclic AMP (cAMP) levels in addition to ATP levels in all 5 cases in both groups. Peripheral lung tissue samples taken 70 minutes and 240 minutes after initiation of EVLP were analyzed to determine cAMP levels. We collected  $2 \times 2$  cm samples from the left upper lobe in every case. We also closed the wound using a running suture to avoid air leaks in every case. The cAMP levels were measured with a cAMP radioimmunoassay kit (Yamasa, Chiba, Japan), as previously reported [3]. Protein levels were measured at the same time points described in the method by Lowry and colleagues [14].

### Perfusate Cytokine Levels

Enzyme-linked immunosorbent assay was used to measure perfusate interleukin (IL)-8 levels 70 and 240 minutes after initiation of EVLP. In all cases, the manufacturer's instructions provided in the IL-8 enzyme-linked immunosorbent assay kits were followed (Quantikine, R&D Systems Inc, Minneapolis, MN).

### Macroscopic and Histologic Findings

Macroscopic appearance of the lungs was recorded 240 minutes after initiation of EVLP. Left lung specimens collected 240 minutes after initiation of EVLP were used for histologic analysis. Each lung was immersed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin.

### Cystic Fibrosis Transmembrane Conductance Regulator

We performed immunofluorescence staining for cystic fibrosis transmembrane conductance regulator (CFTR) on lung samples collected 240 minutes after initiation of EVLP. We used CFTR-specific goat polyclonal IgG (sc-8909; Santa Cruz Biotechnology, Inc, Dallas, TX) as the primary antibody and donkey anti-goat IgG (Alexa 555; Molecular Probes/Life Technologies, Frederick, MD) as the secondary antibody, as previously described [15].

### Statistical Analysis

All statistical analyses were performed using StatView, version 5.0, software (Abacus Concepts, Berkeley, CA). All values are presented as the mean  $\pm$  standard deviation. Data were evaluated using repeated measures analysis of variance, Scheffe's post hoc multiple comparison test, and the Mann-Whitney *U* test. A *p* value of less than 0.05 was considered statistically significant.

### Results

Beagles weighing 9 to 11.6 kg (Kitayama Labes Co, Ltd, Hongo Farm, Yamaguchi, Japan) were used in this study. There were no significant differences in beagle body weights between the control group and the  $\beta_2$  group ( $10.6 \pm 0.8$  kg versus  $10.8 \pm 0.9$  kg).

### Assessment of Lung Function

The  $\beta_2$ -treated group showed significantly lower peak airway pressure and higher dynamic pulmonary compliance than the control group ( $p < 0.001$  and  $p = 0.026$ , respectively) (Figs 2A, 2B). In addition, the pulmonary arterial pressure and PVR in the  $\beta_2$  group was lower than that in the control group ( $p < 0.001$  and  $p = 0.0068$ , respectively) (Figs 2C, 2D). Both groups showed similar  $PO_2$  ( $p = 0.12$ ).




Fig 2. Physiologic lung functions during ex vivo lung perfusion (EVLP). (A) Peak airway pressure. (B) Dynamic pulmonary compliance. (C) Pulmonary artery pressure. (D) Pulmonary vascular resistance. (E)  $PO_2$  of the perfusate from the lung. \* $p < 0.05$  between the  $\beta_2$  group (open circles) and the control group (open boxes) in Scheffe's post hoc multiple comparison test.

### Lung WDR

The lung WDR in the  $\beta_2$  group was significantly lower than that in the control group ( $8.78 \pm 0.61$  versus  $5.72 \pm 0.88$ ;  $p = 0.0027$ ) (Fig 3). This result indicated that the lungs in the control group were more edematous.

### Adenine Nucleotide and cAMP Levels

The  $\beta_2$  group showed higher ATP, ADP, and AMP levels than the control group ( $p = 0.02$ ,  $p = 0.03$ , and  $p = 0.03$ , respectively). Consequently, the  $\beta_2$  group showed higher TAN (TAN = ATP + ADP + AMP) levels than in the control group ( $3.50 \pm 0.58$  nmol/mg versus  $2.17 \pm 0.57$  nmol/mg;  $p = 0.02$ ) (Fig 4).

The cAMP levels 70 minutes after EVLP initiation in the  $\beta_2$  group were significantly higher than those in the control group ( $4.09 \pm 3.42$  pmol/mg versus  $0.58 \pm 0.29$  pmol/mg;  $p = 0.03$ ). Although the cAMP levels decreased 240 minutes after EVLP initiation in the  $\beta_2$  group, they were still higher than those measured in the control group ( $1.23 \pm 0.98$  pmol/mg versus  $0.30 \pm 0.19$  pmol/mg;  $p = 0.03$ ) (Fig 5).

### Cytokine Levels in the Perfusate

Seventy minutes after EVLP initiation, IL-8 levels in the perfusate were very low in both groups. At 240 minutes after EVLP initiation, IL-8 levels increased equally in both groups (Fig 6).

### Macroscopic and Histologic Findings

At 240 minutes after EVLP initiation, the lungs in the control group had more areas of macroscopic, broad, dark red tissue than those in the  $\beta_2$  group (Figs 7A, 7B). On histologic examination, more edematous changes were noted in the control group than in the  $\beta_2$  group (Figs 7C, 7D).

### CFTR Immunofluorescence Staining

CFTR was expressed in the lungs at a higher level in the  $\beta_2$  group than in the control group (Figs 8A, 8B).

### Comment

In this study, we used a canine model of DCD to investigate the effect of  $\beta_2$ -adrenoreceptor agonist inhalation during EVLP. In our study, the  $\beta_2$  group showed better




Fig 3. Lung wet-to-dry weight ratio.




Fig 4. Adenosine nucleotide levels (nmol/mg dry weight) measured 240 minutes after ex vivo lung perfusion (EVLP) (TAN = ATP + ADP + AMP). ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; TAN, total adenosine nucleotide.

lung function (including lower peak airway pressure, higher dynamic pulmonary compliance, lower pulmonary arterial pressure, and lower PVR), lower WDR, higher cAMP levels, higher TAN levels, and more CFTR expression than in the control group. Thus our study indicated that  $\beta_2$ -adrenoreceptor agonist inhalation during EVLP after lung procurement had a protective effect. Our group had previously reported that  $\beta_2$ -adrenoreceptor agonist inhalation during the period before procurement attenuated IRI [2, 3]. In this study, we demonstrated a protective effect of  $\beta_2$ -adrenoreceptor agonist inhalation after procurement. This might be useful in clinical practice, because inhalation after procurement does not affect any other organs.

According to Yeung and colleagues [16], compliance and airway pressure during EVLP are important for evaluating donor graft function. In our study, the  $\beta_2$  group showed significantly lower peak airway pressure and higher dynamic pulmonary compliance than did the control group. These results indicate a protective effect of  $\beta_2$ -adrenoreceptor agonist inhalation during EVLP. Furthermore, lower PVR was confirmed in the  $\beta_2$  group. As pointed out by Mak and colleagues [17],  $\beta_2$ -adrenoreceptors are distributed in pulmonary blood vessels as well as airway epithelial cells, airway smooth muscle, and alveolar walls. Leblais and associates [18] also mentioned




Fig 5. Peripheral lung tissue cyclic AMP (cAMP) levels measured at 70 and 240 minutes after ex vivo lung perfusion (EVLP) initiation.




Fig 6. Perfusate interleukin-8 (IL-8) levels measured at 70 and 240 minutes after *ex vivo* lung perfusion (EVLP) initiation.


that  $\beta_2$ -adrenoreceptors mediate relaxation of the pulmonary artery. Our results were consistent with those of these previous studies. The  $PO_2$  levels in the control group were higher than we expected for at least 2 reasons. First, the perfusion was not a total flow in the current EVLP setting. The perfusate flow was gradually increased to a maximum of 40% of the estimated cardiac output (100 mL/kg) according to the Toronto protocol [16]. As Yeung and colleagues [16] also reported,  $PO_2$  levels fall with increasing perfusion flow in the cellular EVLP. Second, lung injury occurred heterogeneously, and lung injury areas might be underperfused. Hypoxic vasoconstriction might occur in the damaged area; therefore, there might be a low perfusion/ventilation mismatch in the control group. As a result, the control group had high  $PO_2$  levels. One might wonder if this is a good example, supporting the idea that  $PO_2$  levels are not a good marker of lung function when used alone.

$\beta_2$ -Adrenoreceptor agonists have been reported to enhance alveolar fluid clearance (AFC) through a cAMP-dependent mechanism [19]. In our study, the lung WDR in the  $\beta_2$  group was significantly lower than that in the control group. In addition, cAMP levels in the  $\beta_2$  group were significantly higher than those in the control group. These results support the possibility that  $\beta_2$ -adrenoreceptor agonist inhalation stimulated AFC in our model. However, the cAMP levels in the  $\beta_2$  group decreased 240 minutes after EVLP initiation, which may be because procaterol is a short-acting  $\beta_2$  agonist. Further investigation using longer-acting  $\beta_2$  agonists will be required.

The  $\beta_2$  group showed higher ATP and TAN levels. The  $\beta_2$  agonists did not increase ATP and TAN directly. High ATP and TAN levels were associated with lung viability [2]. The  $\beta_2$  agonists attenuated lung injury; therefore,  $\beta_2$  agonists enhanced lung viability, which resulted in high ATP and TAN levels.

Recent studies have demonstrated that  $\beta_2$ -adrenoreceptor agonists enhance AFC through the upregulation of CFTR [20–22]. Here we showed that CFTR expression was higher in the  $\beta_2$ -treated group. In addition, cAMP was reported to play an important role in activating the CFTR promoter [23], and our results were consistent with this reported mechanism. The previous clinical data suggested that the recovery from acute lung injury required the removal of fluid from the alveolar space. Patients with acute lung injury who retained maximal AFC had better clinical outcomes [24]. The upregulation of AFC through the CFTR attenuated lung injury in our study as well. In the previous report, fluid and chloride transport from the airspace was accelerated in the presence of the  $\beta$  agonist

Fig 7. (A and B) Macroscopic and (C and D) histologic findings after 240 minutes of *ex vivo* lung perfusion (EVLP). C and D show hematoxylin and eosin staining at  $\times 400$  magnification. (B) The lungs in the control group have more areas of broad dark red tissues macroscopically than do those in the  $\beta_2$  group (A). (D) The control group showed more edematous changes histologically than did the  $\beta_2$  group (C).






Fig 8. CFTR-expressing cells were visualized by using fluorescent microscopy with Alexa 555 (red). Nuclei were stained with 4',6'-diamidino-2-phenylindole (DAPI) (blue) at  $\times 200$  magnification. (A) The  $\beta_2$  group showed higher CFTR expression in the lungs than did the (B) control group. (CFTR, cystic fibrosis transmembrane conductance regulator.)

isoproterenol within 30 minutes [21]. Additionally, the isoproterenol-induced increase in chloride transport was inhibited by the CFTR inhibitor glibenclamide, providing evidence that the cAMP-stimulated uptake of chloride was mediated by CFTR. In our study, we showed high CFTR expression 3 hours after inhalation of a  $\beta_2$ -adrenoreceptor agonist. These immediate benefits were consistent with the previous report, although the mechanism was not investigated in our study.

IL-8 inhibits cAMP-stimulated alveolar epithelial fluid transport. Roux and colleagues [24] showed that IL-8 decreases the net fluid transport across alveolar epithelial cells through a reduction in CFTR activity and biosynthesis. This reduction was mediated by heterologous  $\beta_2$ -adrenergic receptor desensitization through the G-protein-coupled receptor kinase 2 (GRK2)/phosphatidylinositol-3-kinase (PI3K) signaling pathway. In our study, IL-8 levels were very low at 70 minutes after EVLP initiation, which means that the  $\beta_2$  agonists worked properly under these circumstances. Roman and colleagues [6] stated that IL-8 in the EVLP perfusate rose mainly during the first 6 hours of EVLP. We also do not think that  $\beta_2$  agonists suppress this rise of IL-8, and IL-8 levels in the perfusate rose in both groups in our study. In addition, de Perrot and coworkers [25] mentioned that IL-8 levels increase after reperfusion in human lung transplantation. If IL-8 levels were high,  $\beta_2$ -adrenoreceptor agonists would fail to enhance AFC. Thus, the very low IL-8 levels in the early phase of EVLP were significant in our study.

There were several limitations to our study. First, we assessed lungs only during EVLP. Future studies should include assessment of the entire lung transplantation model. Second, cardiac arrest in this study was induced by intravenous injection of potassium chloride, which is not performed in clinical practice. In this study, we selected this procedure for the uniform induction of cardiac arrest. Third, we mentioned the limitations regarding CFTR immunofluorescence staining. CFTR is expressed in type I and type II alveolar epithelial cells and distal airway epithelium [21]. Thus, we interpreted that CFTR was expressed in alveolar epithelial cells in our study, but we cannot deny that our results were influenced by the viable alveolar macrophages.

In conclusion,  $\beta_2$ -adrenoreceptor agonist inhalation after procurement during EVLP attenuates lung injury in a canine model of lung donation after cardiac death.

We would like to thank Mr. Katsuyoshi Okawa for his expert technical support.

## References

1. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. *Am J Respir Crit Care Med* 2003;167:490–511.
2. Sakamoto J, Chen F, Nakajima D, et al. The effect of beta-2 adrenoreceptor agonist inhalation on lungs donated after cardiac death in a canine lung transplantation model. *J Heart Lung Transplant* 2012;31:773–9.
3. Chen F, Nakamura T, Fujinaga T, et al. Protective effect of a nebulized beta2-adrenoreceptor agonist in warm ischemic-reperfused rat lungs. *Ann Thorac Surg* 2006;82:465–71.
4. Steen S, Sjoberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. *Lancet* 2001;357:825–9.
5. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. *N Engl J Med* 2011;364:1431–40.
6. Roman MA, Nair S, Tsui S, Dunning J, Parmar JS. Ex vivo lung perfusion: a comprehensive review of the development and exploration of future trends. *Transplantation* 2013;96:509–18.
7. Nakajima D, Chen F, Yamada T, et al. Hypothermic machine perfusion ameliorates ischemia-reperfusion injury in rat lungs from non-heart-beating donors. *Transplantation* 2011;92:858–63.
8. Wiebe K, Oezkur M, Poling J, Haverich A. Potential of an injectable polymer to prevent hyperacute rejection of ex vivo perfused porcine lungs. *Transplantation* 2006;82:681–8.
9. Inci I, Ampollini L, Arni S, et al. Ex vivo reconditioning of marginal donor lungs injured by acid aspiration. *J Heart Lung Transplant* 2008;27:1229–36.
10. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. *Sci Transl Med* 2009;1:4ra9.
11. Emaminia A, Lapar DJ, Zhao Y, et al. Adenosine A(2)A agonist improves lung function during ex vivo lung perfusion. *Ann Thorac Surg* 2011;92:1840–6.
12. Valenza F, Rosso L, Coppola S, et al. Beta-adrenergic agonist infusion during extracorporeal lung perfusion: effects on glucose concentration in the perfusion fluid and on lung function. *J Heart Lung Transplant* 2012;31:524–30.
13. Chen F, Nakamura T, Wada H. Development of new organ preservation solutions in Kyoto University. *Yonsei Med J* 2004;45:1107–14.

14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265–75.
15. Cohen JC, Larson JE. Pathophysiologic consequences following inhibition of a CFTR-dependent developmental cascade in the lung. *BMC Dev Biol* 2005;5:2.
16. Yeung JC, Cypel M, Machuca TN, et al. Physiologic assessment of the ex vivo donor lung for transplantation. *J Heart Lung Transplant* 2012;31:1120–6.
17. Mak JC, Nishikawa M, Haddad EB, et al. Localisation and expression of beta-adrenoceptor subtype mRNAs in human lung. *Eur J Pharmacol* 1996;302:215–21.
18. Leblais V, Delannoy E, Fresquet F, et al. Beta-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent beta2 component in pulmonary hypertension. *Cardiovasc Res* 2008;77:202–10.
19. McAuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. *Crit Care Med* 2004;32:1470–6.
20. Jiang X, Ingbar DH, O'Grady SM. Adrenergic regulation of ion transport across adult alveolar epithelial cells: effects on Cl-channel activation and transport function in cultures with an apical air interface. *J Membr Biol* 2001;181:195–204.
21. Fang X, Fukuda N, Barbry P, Sartori C, Verkman AS, Matthay MA. Novel role for CFTR in fluid absorption from the distal airspaces of the lung. *J Gen Physiol* 2002;119:199–207.
22. Fang X, Song Y, Hirsch J, et al. Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. *Am J Physiol Lung Cell Mol Physiol* 2006;290:L242–9.
23. Mutlu GM, Factor P. Alveolar epithelial beta2-adrenergic receptors. *Am J Respir Cell Mol Biol* 2008;38:127–34.
24. Roux J, McNicholas CM, Carles M, et al. IL-8 inhibits cAMP-stimulated alveolar epithelial fluid transport via a GRK2/PI3K-dependent mechanism. *FASEB J* 2013;27:1095–106.
25. De Perrot M, Sekine Y, Fischer S, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. *Am J Respir Crit Care Med* 2002;165:211–5.

## INVITED COMMENTARY

Lung transplantation is a lifesaving treatment for patients with end-stage pulmonary disease; however, its success is limited by significant donor organ shortages because the majority of donor lungs are currently deemed unsuitable. Ex vivo lung perfusion (EVLP) is a technique of normothermic acellular perfusion recently developed to expand the donor lung pool by enabling functional assessment of high-risk donor lungs such as those obtained through donation after cardiac death (DCD). The first clinical application of EVLP was reported by Steen and colleagues [1]; this has been followed by numerous supportive studies, both experimental and clinical. In August 2014, the US Food and Drug Administration approved the XVIVO Perfusion System with Steen solution (XVIVO Perfusion, Göteborg, Sweden) for use in preserving donor lungs that do not initially meet the standard criteria for transplantation. Moreover, the use of EVLP as a platform to therapeutically recondition injured donor lungs has gained rapid attention, which adds yet another strategy for the expansion of the donor lung pool.

In this issue of *The Annals of Thoracic Surgery*, Kondo and colleagues [2] investigate the antiinflammatory aspects of a  $\beta_2$ -adrenoreceptor agonist, procaterol, as a novel strategy to protect DCD donor lungs during EVLP. Although widely used in clinical practice to treat asthma and chronic obstructive pulmonary disease,  $\beta_2$ -adrenoreceptor agonists, including procaterol, have also been reported to have antiinflammatory effects both in vivo and in vitro by modulating the activities of a range of immune and inflammatory cells [3, 4]. The authors performed a simple study in which DCD donor lungs from beagles underwent EVLP with aerosolized procaterol versus a vehicle preparation. After 240 minutes of EVLP with procaterol treatment, the authors noted significantly improved lung function (reduced peak airway pressure, pulmonary artery pressure, and pulmonary vascular resistance along with

increased pulmonary compliance) and reduced pulmonary edema. This was accompanied by elevated cyclic adenosine monophosphate and total adenosine nucleotide levels in treated lungs. Thus the authors concluded that inhalation of a  $\beta_2$ -adrenoreceptor agonist during EVLP attenuates injury in DCD donor lungs.

Despite the limitation that these lungs were not transplanted, these results add to the body of mounting evidence that marginal donor lungs can, in many cases, be reconditioned during EVLP through therapeutic strategies. With future advances in these methodologies, the clinical application of EVLP-mediated therapeutic treatments could soon make a significant impact on the severe shortage of acceptable donor lungs that severely limits the survival of patients on the lung transplant waiting list.

Victor E. Laubach, PhD

Department of Surgery  
University of Virginia School of Medicine  
PO Box 801359  
Charlottesville, VA 22980  
e-mail: laubach@virginia.edu

## References

1. Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. *Lancet* 2001;357:825–9.
2. Kondo T, Chen F, Ohsumi A, et al.  $\beta_2$ -Adrenoreceptor agonist inhalation during ex vivo lung perfusion attenuates lung injury. *Ann Thorac Surg* 2015;100:480–6.
3. Kolmus K, Tavernier J, Gerlo S. Beta-adrenergic receptors in immunity and inflammation: stressing NF-kappa B. *Brain Behav Immun* 2015;45:297–310.
4. Theron AJ, Steel HC, Tintinger GR, Feldman C, Anderson R. Can the anti-inflammatory activities of beta2-agonists be harnessed in the clinical setting? *Drug Des Devel Ther* 2013;7:1387–98.